Halozyme Announces SWOG Will Resume Clinical Trial of PEGPH20 In Combo with Modified FOLFIRINOX for Advanced Pancreatic Cancer
September 18, 2014 at 09:04 AM EDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical ...